Literature DB >> 30864697

Y‑box‑binding protein 1 inhibits apoptosis and upregulates EGFR in colon cancer.

Sachiko Nagasu1, Tomoya Sudo1, Tetsushi Kinugasa1, Takatou Yomoda1, Kenji Fujiyoshi1, Takahiro Shigaki1, Yoshito Akagi1.   

Abstract

Y‑box‑binding protein 1 (YB‑1) is a DNA/RNA‑-binding protein and an important transcription and translation factor in carcinogenesis. However, the biological function and molecular correlation of YB‑1 in colorectal cancer are not fully understood. The aim of the present study was to determine the significance of YB‑1 expression and its biological role in colorectal cancer. Cell proliferation, migration and apoptosis were examined upon knockdown of YB‑1 expression in different colon cancer cell lines that had different genetic backgrounds. Since the properties of different colon cancer cell lines with specific RAS/RAF gene mutations downstream epidermal growth factor receptor (EGFR) may differ from wild‑type colorectal cancer, it is critical to study the role of YB‑1 with respect to the mutational status of RAS. The results indicated that the suppression of YB‑1 decreased cell proliferation (P<0.05) and migration (P<0.05) regardless of the status of RAS/RAF in the HT29, HCT116 and CaCo2 cell lines. In contrast, YB‑1 knockdown altered the expression of apoptosis‑related genes and the expression of EGFR was detected in the cell lines expressing wild‑type RAS/RAF but not in those expressing mutated RAS/RAF. These results indicated that YB‑1 plays an important role in cell proliferation, migration, apoptosis and EGFR expression in colorectal cancer. Furthermore, apoptosis and EGFR expression may be affected by the mutational status of RAS/RAF and controlled through YB‑1.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30864697     DOI: 10.3892/or.2019.7038

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  The predictive value of RNA binding proteins in colon adenocarcinoma.

Authors:  Lipeng Luan; Feng Lu; Xiaochuan Wang; Yunliang Wang; Wei Wang; Yong Yang; Guoliang Chen; Huihui Yao; Xinyu Shi; Zihan Yuan; Guoqiang Zhou; Haitao Zhang; Songbing He
Journal:  J Gastrointest Oncol       Date:  2021-08

2.  ENST00000430471 Promotes Development and Metastasis of Colorectal Cancer by Regulating the Expression of YBX-1.

Authors:  Zhenghai Zhu; Xiaoxin Zhang; Ying Zhou; Jie Cheng; Zipeng Xu
Journal:  Cancer Manag Res       Date:  2020-08-11       Impact factor: 3.989

3.  CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1.

Authors:  Yuxiang Lin; Jie Zhang; Yan Li; Wenhui Guo; Lili Chen; Minyan Chen; Xiaobin Chen; Wenzhe Zhang; Xuan Jin; Meichen Jiang; Han Xiao; Chuan Wang; Chuangui Song; Fangmeng Fu
Journal:  J Transl Med       Date:  2022-01-06       Impact factor: 5.531

4.  Treatment of HT29 Human Colorectal Cancer Cell Line with Nanocarrier-Encapsulated Camptothecin Reveals Histone Modifier Genes in the Wnt Signaling Pathway as Important Molecular Cues for Colon Cancer Targeting.

Authors:  Aisha Farhana; Avin Ee-Hwan Koh; Sangeetha Kothandan; Abdullah Alsrhani; Pooi Ling Mok; Suresh Kumar Subbiah
Journal:  Int J Mol Sci       Date:  2021-11-13       Impact factor: 5.923

5.  YB1 associates with oncogenetic roles and poor prognosis in nasopharyngeal carcinoma.

Authors:  Yuting Zhan; Xianyong Chen; Hongmei Zheng; Jiadi Luo; Yang Yang; Yue Ning; Haihua Wang; Yuting Zhang; Ming Zhou; Weiyuan Wang; Songqing Fan
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

Review 6.  A comprehensive review of the functions of YB-1 in cancer stemness, metastasis and drug resistance.

Authors:  Akram Alkrekshi; Wei Wang; Priyanka Shailendra Rana; Vesna Markovic; Khalid Sossey-Alaoui
Journal:  Cell Signal       Date:  2021-07-03       Impact factor: 4.850

7.  YBX1 promotes tumor progression via the PI3K/AKT signaling pathway in laryngeal squamous cell carcinoma.

Authors:  Jing Zhao; Pu Zhang; Xin Wang
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.